Secondary prevention in the acute and early chronic phase after ischemic stroke and transient ischemic attacks with antiplatelet drugs -is antiplatelet monotherapy still reasonable?.
Introduction
Intravenous thrombolysis with recombinant tissue plasminogen activator is the only proven medical treatment for acute ischemic stroke in a time period up to 4.5 hours after onset of stroke symptoms. However, only a minority of patients is eligible for intravenous thrombolysis due to delayed presentation or contraindications to thrombolysis. In the remaining patients, early prevention of recurrent stroke is one of the primary therapeutic targets. Numerous prospective studies have shown that the risk of a subsequent or recurrent ischemic stroke is highest in the first 48 to 72 hours after the initial cerebrovascular ischemic event (1).
We discuss current evidence from randomised trials concerning secondary stroke prevention with antiplatelets in the acute and early chronic phase after TIA and stroke.
Secondary stroke prevention with aspirin in the acute and early chronic postischemic phase
Early treatment with aspirin in patients with acute ischemic stroke was investigated in two large clinical trials, the International Stroke Trial (IST) and the Chinese Acute Stroke Trial (CAST). IST was a randomised, unblinded trial that recruited a total of 19435 patients with acute ischemic stroke to receive aspirin (300 mg/daily), one of two doses of subcutaneously administered heparin (5000 U/BID or 12500 U/BID), or both, in a factorial design within 48 hours of stroke symptom onset. Among aspirinallocated patients there were non-significantly fewer deaths within 14 days (9.0% vs.
9.4%), corresponding to 4 fewer deaths per 1000 patients. At 6 months, 62.2% of patients treated with aspirin were dead or dependent compared with 63.5% of untreated patients. Patients treated with aspirin had significantly fewer recurrent is -21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w  O  n  l  y   4 chemic strokes within 14 days (2.8% vs. 3.9%) with no significant excess of hemorrhagic stroke (0.9% vs. 0.8%). In contrast to IST, CAST was a randomised placebocontrolled trial. 21.106 patients were treated with aspirin 160 mg/daily or placebo for 4 weeks, starting within 48 hours after symptom onset. There was a significant reduction in mortality during the 4 week treatment period in aspirin-allocated patients (3.3% vs. 3.9%). Furthermore, there were significantly fewer recurrent ischemic strokes in patients treated with aspirin (1.6% vs. 2.1). Treatment with aspirin was associated with a non-significant increase in hemorrhagic strokes (1.1% vs. 0.9).
In a prespecified combined analysis of IST and CAST, aspirin treatment started in the acute post-ischemic stroke phase resulted in a reduction of 10 deaths or recurrent strokes and causes 2 hemorrhagic strokes per 1000 treated patients (2) .
Abciximab in early secondary prevention
The intravenous use of the platelet glycoprotein IIb/IIIa inhibitor abciximab has been considered to be safe when administered within 24 hours after ischemic stroke onset after two phase II trials had been carried out. However, the phase III trial AbESTT-II had to be terminated prematurely after enrolment of 808 patients due to a significantly increased bleeding rate in the active treatment group (3). During the first 5 days of enrolment, 5.5% of patients who had received intravenously administered abciximab within 5 hours of onset of stroke had symptomatic or fatal intracranial hemorrhage versus 0.5% of placebo-treated patients. 5 The combination of aspirin plus dipyridamole has been shown to be more effective than aspirin monotherapy in long-term secondary stroke prevention in the randomised trials ESPS-2 and ESPRIT (4, 5) . However, enrolment of patients in these trials occurred up to 6 months after the cerebrovascular ischemic event. The combination of aspirin (25 mg BID) and extended-release dipyridamole (200 mg BID) was compared with clopidogrel monotherapy (75 mg daily) in more than 20000 patients in the randomised PRoFESS trial (6) . A post-hoc analysis of this trial investigated the 1360 patients who were randomised within 72 hours of ischemic stroke onset (7) . There was no significant difference in death or dependency at 30 days between both antiplatelet regimen. A non-significant trend towards a reduction of recurrent stroke was seen with the combination of aspirin and extended-release dipyridamole at 90 days (1.64% vs. 2.91%; OR 0.56, 95%CI 0.26 to 1.18).
The randomised EARLY trial compared the combination of aspirin (25 mg BID) and extended-release dipyridamole (200 mg BID) with aspirin monotherapy (100 mg/daily) started within 24 hours of symptom onset in patients with ischemic stroke (NIHSS score ≤ 20) or TIA (8) . A total of 543 patients were randomised, 283 receiving aspirin and extended-release dipyridamole (early initiation group) and 260 receiving aspirin monotherapy for the initial 7 days (late initiation group). Thereafter, all patients were treated with the combination antiplatelet therapy. The primary endpoint was an excellent or good functional outcome at 90 days, defined as a value of 0 or 1 on the modified Rankin scale, which was assessed by a blinded investigator using a standardised telephone interview. Vascular events and mortality were also assessed as a composite safety and efficacy endpoint. At day 90, 56% of patients in the early initiation group and 52% of patients treated with aspirin monotherapy during the first 7 days had a modified Rankin scale value of 0 or 1, a difference that was not statisti- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Dual antiplatelet therapy with Clopidogrel and Aspirin in the acute and early chronic secondary stroke prevention
The FASTER trial was a randomised controlled pilot study that compared antiplatelet therapy with clopidogrel and aspirin with aspirin alone in TIA and stroke patients, within 24 hours of symptom onset (9) . 392 patients were randomised to an initial loading dose of 300 mg Clopidogrel followed by 75 mg daily or placebo. All patients received 180 mg aspirin daily. The primary outcome was an ischemic or hemorrhagic stroke within 90 days, which did not significantly differ between both treatment arms (7.1% on clopidogrel had an ischemic stroke vs. 10.8% on placebo). Intracranial hemorrhage occurred in 2 patients in the clopidogrel group. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This finding suggests that there is unlikely to be a large rebound effect after discontinuation of a 30-day course of clopidogrel and aspirin in acute TIA and minor ischemic stroke. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Considering the available evidence, patients with an acute TIA or minor ischemic stroke might benefit from combination of aspirin plus clopidogrel or aspirin plus dipyridamole for at least 30 days. However, one has to keep in mind that most of the available data has been derived from meta-analyses of non-prespecified subgroups from randomised trials. Thus, a possible bias or confounding factors cannot be excluded. There is good evidence from randomised trials for the combination of aspirin and dipyridamole both in the acute, early and long term secondary stroke prevention.
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